Galena Biopharma Presents GALE-401 (Anagrelide Controlled

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Phase 2 Data at the European Hematology Association 20th Congress
  • GALE-401 was well tolerated with primarily Grade 1 and 2 toxicities
  • Phase 2 pilot study demonstrated an Overall Response Rate of 78%

PORTLAND, Ore., June 15, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq: GALE ), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that data from the Company's Phase 2 clinical trial of GALE-401 was presented at the European Hematology Association 20 th Congress in Vienna, Austria. The GALE-401 Phase 2 pilot study is a single arm, open label, multi-center study evaluating the efficacy and safety of anagrelide controlled release in subjects with thrombocytosis secondary to essential thrombocythemia (ET) and other myeloproliferative neoplasms (MPNs).

The poster presentation, entitled, " Phase 2 Study of a Novel Controlled-Release Formulation of Anagrelide (GALE-401) in Subjects with Myeloproliferative Neoplasm (MPN)-Related Thrombocytosis," was presented on Saturday, June 13, 2015. The Phase 2 study demonstrated that GALE-401 was well tolerated with primarily Grade 1 and 2 toxicities in 16 of the 18 subjects enrolled. The efficacy shown in the trial compares favorably to historical anagrelide immediate release (IR) response rates with the following platelet response: overall response rate (ORR) of 78% (14/18); complete response (CR) of 39% (7/18); partial response (PR) of 39% (7/18). The median time to response was 5 weeks (range, 3–10), and the median duration of response has not yet been reached. Based on the data, the investigators concluded that GALE-401 remains a viable potential treatment option for MPNs, and a randomized trial comparing GALE-401 versus anagrelide IR is warranted. Final data from the GALE-401 Phase 2 trial is expected to be presented at the American Society of Hematology conference in December.

"We are encouraged by this initial trial in MPN patients showing GALE-401 is well tolerated with an overall response rate of 78%," said Mark W. Schwartz, Ph.D., President and Chief Executive Officer. "We expect to report more mature data on the trial this Fall, and are evaluating potential next steps to further advance GALE-401 in the clinic. We are grateful to the patients who volunteered for this trial and for the site staff and investigators who continue to work with us to treat these patients and advance the asset."

"Myeloproliferative neoplasms are progressive blood cancers that can strike anyone at any age, and is a condition patients live with for the rest of their lives. This first-in-patient data from anagrelide controlled release is promising as a potential treatment option for these patients and warrants an additional trial to further assess the characteristics of the agent and its potential," added Srdan Verstovsek, M.D., Ph.D., Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, and principal investigator for the Phase 2 trial.

The primary objective of the study was to estimate ORR with the secondary objectives of safety, tolerability and pharmacokinetics (PK). Enrolled patients were adult men and women diagnosed with an MPN-related elevated platelet count to include chronic myelogenous leukemia (CML), polycythemia vera (PV), primary myelofibrosis (PMF), or ET. Patient eligibility requirements also included:

  • Platelet count ≥ 600 K/μL on two occasions at least 14 days apart prior to first dose of study drug
  • MPN diagnosis other than ET, concurrent anti-MPN treatment was permitted, provided that the doses are stable at least 4 weeks prior to first dose of study drug
  • Currently not receiving therapy specifically intended to reduce platelet counts
  • Adequate hepatic function

GALE-401 was administered at a starting dose of 0.5 mg twice daily (1.0 mg/day). The dose was titrated at weekly intervals, on an individual basis, to determine the lowest dose required to achieve and maintain a target platelet count of 150–400 K/μL. Platelet response is defined as complete response (CR, ≤ 400 K/μL) or partial response (PR, ≤ 600 K/μL or ≥ 50% reduction from baseline) maintained for at least 4 weeks.

About GALE-401 (Anagrelide Controlled Release)

GALE-401 (Anagrelide Controlled Release) contains the active ingredient anagrelide. The currently available immediate release formulation (Agrylin ® or anagrelide IR) is approved by the FDA for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. Adverse events associated with anagrelide IR, such as nausea, diarrhea, abdominal pain, palpitations, tachycardia, and headache, may be dose and plasma concentration dependent. Reducing the maximum plasma concentration (C max ) is expected to reduce side effects, but preserve efficacy. GALE-401 is a reformulated, controlled release version of anagrelide. A Phase 2 pilot study with GALE-401 is ongoing. Preliminary data has demonstrated that the agent is well tolerated with primarily Grade 1 and 2 toxicities. The efficacy shown in the trial compares favorably to historical anagrelide IR response rates with an overall response rate (ORR) of 78% (n=14/18). Final data from the GALE-401 Phase 2 trial is expected to be presented at the American Society of Hematology conference in December.

About Myeloproliferative Neoplasms

Myeloproliferative neoplasms (MPNs) are a closely related group of hematological malignancies in which the bone marrow cells that produce the body's blood cells develop and function abnormally. The main MPNs are polycythemia vera (PV), chronic myelogenous leukemia (CML), primary myelofibrosis (PMF), essential thrombocythemia (ET), and all of which are associated with high platelet counts. The MPNs are progressive blood cancers that can strike anyone at any age, and for which there is no known cure.

About Galena Biopharma

Galena Biopharma, Inc. (Nasdaq: GALE ) is a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care. Galena's development portfolio ranges from mid- to late-stage clinical assets, including a robust immunotherapy program led by NeuVax™ (nelipepimut-S) currently in an international, Phase 3 clinical trial. The Company's commercial drugs include Abstral ® (fentanyl) Sublingual Tablets and Zuplenz ® (ondansetron) Oral Soluble Film. Collectively, Galena's clinical and commercial strategy focuses on identifying and advancing therapeutic opportunities to improve cancer care, from direct treatment of the disease to the reduction of its debilitating side-effects. For more information, visit www.galenabiopharma.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the progress of the commercialization of Abstral ® and development of Galena's product candidates, including patient enrollment in our clinical trials, as well as statements about our expectations, plans and prospects. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those identified under "Risk Factors" in Galena's Annual Report on Form 10-K for the year ended December 31, 2014 and most recent Quarterly Reports on Form 10-Q filed with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements. Galena does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this press release.

Abstral and NeuVax are trademarks of Galena Biopharma, Inc. All other trademarks are the property of their respective owners.

Remy Bernarda SVP, Investor Relations & Corporate Communications (503) 405-8258

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Inventor Launches Handy Solution for Kids' Car Sickness

Updated Category News Views 29

A Fresh Take on an Age-Old Problem Just when you thought the universe had thrown all it could at beleaguered parents, here comes a nifty little accessory tackling those dreaded uphill battles with kids and car rides. Some bright spark from Middleburgh, New York, sick of scrubbing car seats and clothing every other road trip, came up with a clever little invention named...

Continue Reading
Go NYC's Perks: Making Commutes Rewarding in NYC

Updated Category News Views 88

Go NYC's Perks: Turning Commutes into Gains I’ve seen a lot of schemes aimed at getting folks to change their travel habits, but this one from Go NYC caught my attention. These guys are trying to squeeze some extra value out of the daily grind for anyone hoofing it across the Big Apple. A new rewards program named Perks kicks off, offering all kinds of discounts and...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 185

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Priceline's Cyber Week: A Pocket-Friendly Travel Bonanza

Updated Category News Views 183

Unpacking Priceline's Cyber Week Bonanza Alright, folks, grab your booking hats because Priceline is back with its annual Cyber Week extravaganza, aiming to give travelers a shot in the arm of savings just when inflation has everyone pinching pennies. From November 16 through December 2, Priceline rolls out the red carpet for vacation planners, offering eye-popping...

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 187

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading
Medtronic's Bold Move to Own Carotid Market Full-Scale

Updated Category News Views 163

When a giant like Medtronic makes a move, you can bet investors take notice, and this latest acquisition is no exception. They’re reaching into their deep pockets to acquire Contego Medical, a company shaking up the world of carotid artery disease treatments. It’s a tactical strike to solidify their leadership in cardiovascular solutions. Medtronic's Bet on Innovation...

Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut

Updated Category News Views 91

A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...

Continue Reading
Veterans Find a Haven in Home Helpers® Franchise

Updated Category News Views 108

Veterans Thriving at Home Helpers® Tossing out a warm welcome to fresh horizons post-military, Home Helpers® Home Care is serving up more than just compassionate care—it’s become a bonafide haven for veterans diving into the world of franchising. This isn’t just an indie pat on the back; according to the latest scoop from Franchise Business Review, Home Helpers®...

Continue Reading
Xiong'an New Area: People's Priorities Reshape Living Spaces

Updated Category News Views 78

Building a City for the People This here is about prioritizing people over skylines. Xiong'an New Area in Hebei Province is shaping up to be more than just a place on the map; it's an experiment in redefining urban living. Skyscrapers and traffic jams? Not on this menu. Instead, nature paves a graceful dance floor between mid-rise residences. Forget your bustling city...

Continue Reading
Better Life Science: Revolutionizing At-Home STI Testing

Updated Category News Views 164

Paving a New Path for STI Testing Accessibility The landscape of STI testing is undergoing a significant shift, and Better Life Science is at the helm with their innovative STD Hero at-home testing service. With a splash in the latest AVN report, they're turning heads in both the clinical world and in mainstream society. This ain't just about checking boxes in health...

Continue Reading

Top 5 Most Recently Viewed Articles

H&E Equipment Services Reveals Q3 2024 Performance Insights

Updated Category News Views 338

H&E Equipment Services Reports Q3 2024 Financial Results H&E Equipment Services, Inc. (NASDAQ: HEES), commonly known as H&E Rentals, recently issued its financial results for the third quarter of 2024. The Company has made significant strides in expanding its branch network, adding eight new locations during the quarter, which brings its total to 157 branches across...

Continue Reading
Automotive V2X Market Trends: A Roadmap to 2031

Updated Category News Views 148

Automotive V2X Market Growth Insights The automotive V2X (Vehicle-to-Everything) market is set for a remarkable transformation, anticipated to expand with a compound annual growth rate of 25.1% from 2024 to 2031. The market is projected to reach a size of US$2.3 billion by 2031. Insights from recent research indicate a shift in dynamics within this evolving market,...

Continue Reading
Toll Brothers Celebrates New Luxury Amenities in Forestville Village

Updated Category News Views 250

Toll Brothers Introduces Exceptional Amenities Toll Brothers, Inc. (NYSE:TOL), a well-respected name in luxury homebuilding, recently celebrated the opening of a fantastic amenity center at Forestville Village. This vibrant community in Knightdale features beautifully designed single-family homes and townhomes, now enhanced with access to resort-style amenities. A...

Continue Reading
Acadia Pharmaceuticals Celebrates Strong Q3 2024 Financial Growth

Updated Category News Views 58

Acadia Pharmaceuticals Reports Financial Results for Q3 2024 Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) has shared encouraging financial results for the third quarter of 2024. The company has showcased a remarkable performance that reflects its strong commercial presence and growth within the pharmaceutical industry. This report provides insights into the company's...

Continue Reading
Crowley Enhances Logistics for Wreaths Across America Initiative

Updated Category News Views 208

Crowley Enhances Logistics for Wreaths Across America Initiative Crowley is taking significant steps to expand its logistical support for the Wreaths Across America program, reflecting its strong commitment to honoring U.S. military personnel. The company is facilitating this through financial sponsorship along with in-kind transportation and logistics services. Expanded...

Continue Reading